Biotech has been the best-performing niche in healthcare in 2017, with the iShares
Nasdaq Biotech index up 40 per cent year-to-date.
By comparison, the
Nasdaq Biotech Index (IBB) has fallen around 25% over that same time frame.
The
Nasdaq Biotech Index saw five pullbacks of more than 6.
The
Nasdaq biotech index gave close to 30 per cent returns compared to the MSCI world index, which gave close to 5 per cent.
Biotech stocks, as measured by the
Nasdaq Biotech Index (NBI), have risen 50% over the past year, in part due to a spate of mergers and acquisitions as big pharmaceutical companies seek to bolster their pipelines of experimental drugs.
The
Nasdaq Biotech Index includes companies classified under the Financial Times Stock Exchange's global system as either biotechnology or pharmaceutical.
The Biotechnology Industry Organization reports that the
Nasdaq biotech index surged 46% in 2003, helping biotech companies amass $16.
After the March 13 announcement to that effect by President Bill Clinton and British Prime Minister Tony Blair, the
NASDAQ Biotech Index lost one-eighth of its value in two days.
The
Nasdaq Biotech Index (NBI) is up 27% year-to-date, beating the S&P 500 by a factor of 3.
Overall, the
Nasdaq Biotech Index plummeted 12 percent.
Biotechnology: Between 1992 and 1995, the
Nasdaq biotech index fell by 70%.
BOSTON -- EvaluatePharma([R]), the premier source for pharmaceutical and biotechnology sector analysis and consensus forecasts, today released a report, titled "Surveying Tomorrow's BioPharma Landscape: The
NASDAQ Biotech Index Up Close," which shows that the quantity of biologic drugs on the market will likely soar by 2018.
